Patents Assigned to Pfizer
  • Oxazole compounds for the treatment of neurodegenerative disorders
    Patent number: 7112599
    Abstract: The present invention relates to compounds of the Formula wherein R3, R5, R6, R7, and Z, and other variables enumerated under one or more of R3, R5, R6, R7, and Z, are as defined. Compounds of the Formula I have activity inhibiting production of A?-peptide. This invention also relates to pharmaceutical compositions and methods of treating diseases, for example, neurodegenerative diseases, e.g., Alzheimer's disease, in a mammal comprising compounds of the Formula I.
    Type: Grant
    Filed: August 5, 2004
    Date of Patent: September 26, 2006
    Assignee: Pfizer Inc.
    Inventor: Yuhpyng L. Chen
  • Processes for preparation of 9,11-epoxy steroids and intermediates useful therein
    Patent number: 7112669
    Abstract: Intermediates in the preparation of 9,11-epoxy steroids are disclosed. Particularly, disclosed are 11,12-epoxy steroid, 4,5-9,11-diepoxy steroid and 12-keto steroid intermediates.
    Type: Grant
    Filed: February 7, 2005
    Date of Patent: September 26, 2006
    Assignee: Pharmacia Corporation (of Pfizer, Inc.)
    Inventors: John S. Ng, Chin Liu, Dennis K. Anderson, Jon P. Lawson, Joseph J. Wieczorek, Sastry A. Kunda, Leo J. Letendre, Mark J. Pozzo, Yuen-Lung L. Sing, Ping T. Wang, Edward E. Yonan, Richard M. Weier, Thomas R. Kowar, Julio A. Baez, Bernhard Erb
  • Portable position determining device
    Patent number: 7113126
    Abstract: A position determining device is disclosed comprising a satellite navigation receiver for automatically providing computed position information, when the device has changed its position relative to a predetermined location, to a paging transmitter for transmission to a paging receiver for readout of the computed position information. The readout may be in the form of coordinates and may be accompanied by a message or alarm. The device may be configured as a portable unit of small size and economical manufacture.
    Type: Grant
    Filed: November 11, 2002
    Date of Patent: September 26, 2006
    Assignee: Pfizer, Inc.
    Inventors: Jennifer Durst, Eugene F. Fowler, Joseph C. McAlexander
  • Methods for expressing and recovering human monoclonal antibodies to CTLA-4
    Patent number: 7109003
    Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.
    Type: Grant
    Filed: July 1, 2003
    Date of Patent: September 19, 2006
    Assignees: Abgenix, Inc., Pfizer Inc.
    Inventors: Douglas Charles Hanson, Mark Joseph Neveu, Eileen Elliott Mueller, Jeffrey Herbert Hanke, Steven Christopher Gilman, C. Geoffrey Davis, Jose Ramon Corvalan
  • Substituted benzopyran derivatives for the treatment of inflammation
    Patent number: 7109211
    Abstract: A class of benzopyran, derivatives is described for use in treating cyclooxygenase-2 mediated disorders. Compounds of particular interest are defined by Formula I? wherein X, A1, A2, A3, A4, R, R?, R1 and R2 are as described in the specification.
    Type: Grant
    Filed: August 19, 2004
    Date of Patent: September 19, 2006
    Assignee: Pharmacia Corporation (of Pfizer, Inc.)
    Inventors: Jeffery S Carter, Mark G Obukowicz, Balekudru Devadas, John J Talley, David L Brown, Matthew J Graneto, Stephen R Bertenshaw, Donald J. Rogier, Jr., Srinivasan Raj Nagarajan, Cathleen E Hanau, Susan J Hartmann, Cindy L Ludwig, Suzanne Metz, Donald E Korte
  • Pyrimidine derivatives for the treatment of abnormal cell growth
    Patent number: 7109335
    Abstract: The present invention relates to a compound of the formula 1 wherein R1–R4 are as defined herein. Such novel pyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: December 11, 2003
    Date of Patent: September 19, 2006
    Assignee: Pfizer Inc
    Inventors: John Charles Kath, Michael Joseph Luzzio
  • Controlled-release dosage forms of azithromycin
    Patent number: 7108865
    Abstract: A controlled-release dosage form of azithromycin having an improved side effect profile; a process for preparing the dosage form; and a method of treating a microbial infection, comprising administering azithromycin in such a controlled-release dosage form to a mammal, including a human patient, in need of such treatment.
    Type: Grant
    Filed: March 9, 2001
    Date of Patent: September 19, 2006
    Assignee: Pfizer Inc
    Inventors: William J. Curatolo, Hylar L. Friedman, Richard W. Korsmeyer, Steven R. LeMott
  • Pharmaceutical combination
    Patent number: 7107985
    Abstract: The present invention relates to a combination comprising (a) an adenosine A2a receptor agonist as define herein and (b) an adrenergic ?2 receptor agonist, for simultaneous, sequential or separate administration by the inhaled route in the treatment of an obstructive airways or other inflammatory disease.
    Type: Grant
    Filed: September 2, 2005
    Date of Patent: September 19, 2006
    Assignee: Pfizer, Inc.
    Inventor: Michael Yeadon
  • Pyrimidine derivatives for the treatment of abnormal cell growth
    Patent number: 7109337
    Abstract: The present invention relates to a compound of the formula 1 wherein R1–R4 are as defined herein. Such novel pyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: May 12, 2005
    Date of Patent: September 19, 2006
    Assignee: Pfizer Inc
    Inventors: John Charles Kath, Michael Joseph Luzzio
  • Crystal forms of azithromycin
    Patent number: 7105179
    Abstract: The invention relates to novel crystal forms of azithromycin, an antibiotic useful in the treatment of infections.
    Type: Grant
    Filed: May 6, 2005
    Date of Patent: September 12, 2006
    Assignee: Pfizer Inc.
    Inventors: Zheng J. Li, Andrew V. Trask
  • Oxazolyl-pyrazole derivatives as kinase inhibitors
    Patent number: 7105535
    Abstract: Compounds which are oxazolyl-pyrazole derivatives, as defined in the specification, and pharmaceutically acceptable salts thereof; are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, viral infections, autoimmune diseases and neurodegenerative disorders.
    Type: Grant
    Filed: January 28, 2002
    Date of Patent: September 12, 2006
    Assignee: Pfizer Italia S.R.L.
    Inventors: Daniela Berta, Eduard Felder, Anna Vulpetti, Marzia Villa
  • Piperazinyl-aryloxy and piperazinyl-heteroaryloxy-n-aryl lactams
    Patent number: 7101885
    Abstract: The present invention relates to compounds of formula I wherein Ar, Y and G are as defined in the specification, a is 1 to 4, Z and W are carbon or nitrogen and n is 1, 2 or 3; and to pharmaceutical compositions comprising the compound of formula I and a pharmaceutically effective carrier; and to a method useful in treating or preventing in mammals, including humans, a disorder or condition selected from the group consisting of anxiety, depression, dysthymia, major depressive disorder, migraine, post-traumatic stress disorder, avoidant personality disorder, borderline personality disorder and phobias.
    Type: Grant
    Filed: June 15, 2004
    Date of Patent: September 5, 2006
    Assignee: Pfizer Inc
    Inventors: John Lowe, III, Mark A. Sanner
  • 2,4-diaminopyrimidine compounds useful as immunosuppressants
    Patent number: 7101869
    Abstract: Novel compounds according to the formula and pharmaceutically acceptable salts, solvates, or hydrates thereof; wherein each occurrence of A is independently selected from CH or N; X is selected from the group consisting of —CH2—, —O—, —NH—, (C1-C6)alkylamino-, (C1-C6)alkylaminocarbonylamino-, (C1-C6)alkylcarbonylamino-, (C1-C6)alkylsulfonylamino-, phenylsulfonylamino-, carbonyl, —NH—C(O)—, —N(C1-C6)alkyl-C(O)—, —S(O)y— where y is 0, 1 or 2, and; n in —(CH2)n— is 1, 2 or 3; and R1, R2, and R3 are as described herein; pharmaceutical compositions that including these compounds, and methods for the treatment of autoimmune disease, inflammation, allergy, transplant rejection, and other circumstances where administration of an immunosuppressive agent is of therapeutic benefit.
    Type: Grant
    Filed: November 22, 2002
    Date of Patent: September 5, 2006
    Assignee: Pfizer Inc.
    Inventors: Todd A. Blumenkopf, Eileen Elliott Mueller, Eric Jan Roskamp
  • Tetrahydroquinolines
    Patent number: 7101881
    Abstract: The present invention relates to compounds of formula I wherein X and Y are as defined in the specification, and to pharmaceutical compositions comprising the compound of formula I and a pharmaceutically effective carrier; and to a method useful in treating or preventing in mammals, including humans, a disorder or condition selected from the group consisting of anxiety, depression, dysthymia, major depressive disorder, migraine, post-traumatic stress disorder, avoidant personality disorder, borderline personality disorder and phobias.
    Type: Grant
    Filed: May 24, 2004
    Date of Patent: September 5, 2006
    Assignee: Pfizer Inc
    Inventor: John Lowe, III
  • Dosing device
    Patent number: 7093594
    Abstract: A dosing device comprising a dispenser (26) for dispensing a dose material and a dose actuation mechanism (44) is provided. The dose actuation mechanism (44) comprises a number of integrally hinged links (52, 54, 55) which are connected to each other at hinging points. A deflectable tongue (157), moveable in response to air flow from inhalation by a patient is attached to a first link (52), to move the first link in response to air flow, movement of the first link being transferred to a second link (54) to cause actuation of the dispenser. The first link rests at an over center, or stable, position prior to operation, and moves under center during operation of the device to trigger movement of the second link. The dose actuation mechanism is a one-piece moulding from plastics material.
    Type: Grant
    Filed: September 24, 2001
    Date of Patent: August 22, 2006
    Assignee: Pfizer Limited
    Inventors: Nigel Harrison, Daniel Godfrey
  • Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof
    Patent number: 7094930
    Abstract: The present invention is directed to certain pharmaceutically acceptable salts of the therapeutically potent selective serotonin reuptake inhibitor, sertraline: and pharmaceutical compositions thereof, wherein said salts are selected from the group consisting of the p-toluenesulfonic acid salt, the fumaric acid salt, the benzenesulfonic acid salt, the benzoic acid salt, the L-tartaric acid salt and the (?)-camphor-10-sulfonic acid salt.
    Type: Grant
    Filed: January 22, 2004
    Date of Patent: August 22, 2006
    Assignee: Pfizer Inc
    Inventors: George J. Quallich, Lewin T. Wint
  • 2-aminocarbonyl-9H-purine derivatives
    Patent number: 7094769
    Abstract: The present invention relates to compounds of the formula: and pharmaceutically acceptable salts and solvates thereof, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such compounds.
    Type: Grant
    Filed: October 1, 2003
    Date of Patent: August 22, 2006
    Assignee: Pfizer Inc
    Inventors: Simon J. Mantell, Peter T. Stephenson
  • Inhibitors of checkpoint kinases (Wee1 and Chk1)
    Patent number: 7094798
    Abstract: This invention relates to pyrrolocarbazole derivatives according formula I wherein R1, R2, R7, R8, R9, X and Y are as defined in the specification wherein said derivatives specifically inhibit one or both of the checkpoint kinases Wee1 and Chk1
    Type: Grant
    Filed: April 25, 2003
    Date of Patent: August 22, 2006
    Assignee: Pfizer Inc
    Inventors: Richard John Booth, Ellen Myra Dobrusin, Alan Kraker, Lorna Helen Mitchell, William Alexander Denny, Jeffrey Bruce Smaill, Andrew Mark Thompson, Florence Oliver Joseph McCarthy, Ho Huat Lee, Brian Desmond Palmer
  • Pyrrolo[2,3-D]pyrimidine compounds
    Patent number: 7091208
    Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.
    Type: Grant
    Filed: August 24, 2005
    Date of Patent: August 15, 2006
    Assignee: Pfizer Inc.
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Michael J. Munchhof
  • Beta-lactamase inhibitor prodrug
    Patent number: 7091197
    Abstract: Prodrugs of 6-?-hydroxymethylpenicillanic acid sulfone having the structure wherein R is H or methyl, and solvates thereof, are disclosed. Also disclosed are pharmaceutical compositions comprising a prodrug of the present invention or a solvate thereof, an optional beta-lactam antibiotic and a pharmaceutically acceptable excipient. Further disclosed is a method for increasing the therapeutic effectiveness of a beta-lactam antibiotic in a mammal by administering an effective amount of a beta-lactam antibiotic and an effectiveness-increasing amount of a prodrug of the present invention, or a solvate thereof. Additionally disclosed is a method for treating a bacterial infection in a mammal by administering a therapeutically effective amount of a pharmaceutical composition of the present invention to a mammal in need thereof.
    Type: Grant
    Filed: August 25, 2003
    Date of Patent: August 15, 2006
    Assignee: Pfizer Inc.
    Inventors: Anthony Marfat, Dale G. McLeod
  • Method and apparatus for dewatering
    Patent number: 5236596
    Abstract: A method and apparatus for dewatering an aqueous coal slurry includes imparting high shear forces to the aqueous coal slurry in the presence of a peptizing agent to render coal particles hydrophobic by stripping clay from the coal particles and peptizing the clay in the aqueous medium of the slurry. The slurry is separating to recover coal particles and the aqueous medium is draining medium from the hydrophobic surface of the coal particles.
    Type: Grant
    Filed: July 24, 1991
    Date of Patent: August 17, 1993
    Inventor: Edward H. Greenwald, Sr.